FilingReader Intelligence
Jiuzhou Pharma gets dapagliflozin API approval
July 28, 2025 at 09:10 AM UTC•By FilingReader AI
Zhejiang Jiuzhou Pharmaceutical announced receiving approval for its dapagliflozin API from the National Medical Products Administration. The company's total R&D investment for this API is approximately RMB 5.05 million.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:603456•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Zhejiang Jiuzhou Pharmaceutical publishes news
Free account required • Unsubscribe anytime